Skip to main content
HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
Abstract #CR05
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Alicia K. Morgans, MD; Neal D. Shore, MD; Nasreen Khan, PhD; Niculae Constantinovici, MD; Javeed Khan, MSc, et al.
Read More
HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
Abstract #CR06
Read More
HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
Abstract #CR07
Read More
HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
Abstract #CR08
Read More
HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
Abstract #CR09
Read More
HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
Abstract #CR10
Read More
HOPA Abstracts
Incidence and Outcomes of Pneumonitis/Interstitial Lung Disease in Patients Receiving Trastuzumab Deruxtecan
Abstract #CR11
Read More
HOPA Abstracts
Number-Needed-to-Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
Abstract #CR13
Read More
HOPA Abstracts
Pharmacist-Led Monitoring for Patients Initiating PARP Inhibitor Therapy
Abstract #CR16
Read More
HOPA Abstracts
Patient Perspective: Logistics of Intravenous Iron Administration and Adherence to Therapy
Abstract #CR15
Read More
Page 21 of 197
Results 201 - 210 of 1963